NeuroPace, Inc. NPCE
12.31 USD -0.03 (-0.24%)
At closeNov 3, 2026, 4:01 PM EST
12.31 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
12.00 Day range 12.64
9.23 52-week range 19.60
- YTD
- -20.27%
- 1 year
- +30.96%
- Market cap
- 422.53M
- Revenue (ttm)
- 76.45M
- Profit margin
- -36.74%
- EPS (ttm)
- -0.57
- Shares out
- 29.85M
- Forward P/E
- -10.90
- YTD return
- -20.27%
- 1-year return
- +30.96%
- Volume
- 199.83K
- Avg volume
- 137.43K
- Open
- 12.42
- Previous close
- 12.34
- Day's range
- 12.00 – 12.64
- 52-week range
- 9.23 – 19.60
- Beta
- 1.80
- Analysts
- Strong Buy
- Price target
- 16.17 (+31.3%)
- Earnings date
- Aug 13, 2024
2Y +5.94 (+93.25%)
Key statistics
- Enterprise value
- 360.82M
- PEG ratio
- 0.00
- Price / sales
- 4.47
- Price / book
- 34.67
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 28.20%
- Free cash flow
- -9.62M
- Total cash
- 56.83M
- Total debt
- 73.50M
- Return on equity
- -214.55%
- Short % of float
- 1.70%
- 50-day average
- 8.74
- 200-day average
- 8.98
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 16.17 +31.3% upside
Now 12.31
- Target (low)
- 13.00
- Target (mean)
- 16.17
- Target (high)
- 20.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -0.24798.
Financials — quick view
NPCE Revenue — quarterly 22.83M
NPCE Net income — quarterly -6.20M
NPCE EPS — quarterly -0.18
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.26 | -0.19 | +0.07 | +26.92% |
| Aug 13, 2024 | Jun 1, 2024 | -0.29 | -0.26 | +0.03 | +10.34% |
| Aug 13, 2024 | Jun 1, 2024 | -0.29 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -0.32 | -0.32 | 0.00 | 0.00% |
| May 8, 2024 | Mar 1, 2024 | -0.32 | — | — | — |
| Mar 5, 2024 | Dec 1, 2023 | -0.33 | -0.23 | +0.10 | +30.30% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | JP Morgan | main | Overweight | Overweight |
| Nov 13, 2024 | Wells Fargo | main | Overweight | Overweight |
| Aug 14, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Aug 14, 2024 | Wells Fargo | main | Overweight | Overweight |
| Jul 15, 2024 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| May 9, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
About NeuroPace, Inc.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- neuropace.com
News
CapsoVision (NASDAQ:CV) and NeuroPace (NASDAQ:NPCE) Critical Contrast 
This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday 
Keybanc Initiates Coverage On NeuroPace with Overweight Rating, Announces Price Target of $18 
Bank of America Corp DE Sells 145,741 Shares of NeuroPace, Inc. $NPCE 
Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report? 
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now 
2,477,603 Shares in NeuroPace, Inc. $NPCE Bought by BlackRock Inc. 
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference 
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference 
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth
Your note
Sign in to keep a note on NPCE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BECKER JOEL | Chief Executive Officer | Stock Award(Grant) | Feb 26, 2024 | 52,470 |
| FAVET MICHAEL | Chief Executive Officer | Stock Award(Grant) | Feb 20, 2023 | 407,080 |
| KCK, LTD. | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 24, 2024 | 5,270,840 |
| KUHN REBECCA | Chief Financial Officer | Stock Award(Grant) | Feb 26, 2024 | 152,204 |
| MORRELL MARTHA J | Officer | Stock Award(Grant) | Feb 26, 2024 | 90,262 |
| ORBIMED ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | May 2, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Orbimed Advisors LLC. | 11.41% | 3,406,335 | 38.97M | Sep 29, 2024 |
| Morgan Stanley | 8.36% | 2,494,341 | 28.54M | Sep 29, 2024 |
| Soleus Capital Management, L.P. | 8.15% | 2,433,168 | 27.84M | Sep 29, 2024 |
| Kent Lake PR LLC | 4.19% | 1,250,000 | 14.30M | Sep 29, 2024 |
| Vanguard Group Inc | 3.33% | 995,196 | 11.39M | Sep 29, 2024 |
| Millennium Management Llc | 2.48% | 739,993 | 8.47M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.35% | 700,523 | 8.01M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 0.97% | 289,128 | 3.31M | Oct 30, 2024 |
| Fidelity Small Cap Growth Fund | 0.61% | 180,773 | 2.07M | Aug 30, 2024 |
| Vanguard Extended Market Index Fund | 0.54% | 161,646 | 1.85M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.47% | 139,423 | 1.59M | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.39% | 116,945 | 1.34M | Oct 30, 2024 |